Research graph
References from Clinician Decision Making in Managing Primary Aldosteronism: A Qualitative Study. Local targets link to admitted publications; unresolved targets remain external evidence.
Unresolved reference
2023 · External reference
Unresolved reference
2021 · External reference
Study heterogeneity and estimation of prevalence of primary aldosteronism: a systematic review and meta-regression analysis
10.1210/jc.2016-1472 · 2016 · External reference
Detecting primary aldosteronism in Australian primary care: a prospective study
10.5694/mja2.51438 · 2022 · External reference
Primary aldosteronism: changing definitions and new concepts of physiology and pathophysiology both inside and outside the kidney
10.1152/physrev.00026.2015 · 2016 · External reference
Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice
10.1016/j.jacc.2017.01.052 · 2017 · External reference
Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis
10.1016/s2213-8587(17)30319-4 · 2018 · External reference
Long-term cardio- and cerebrovascular events in patients with primary aldosteronism
10.1210/jc.2013-2805 · 2013 · External reference
Guidelines for primary aldosteronism: uptake by primary care physicians in Europe
10.1097/hjh.0000000000001088 · 2016 · External reference
Diagnostic rate of primary aldosteronism in Emilia-Romagna, Northern Italy, during 16 years (2000-2015)
10.1097/hjh.0000000000001384 · 2017 · External reference
Outcomes of a specialized clinic on rates of investigation and treatment of primary aldosteronism
10.1001/jamasurg.2021.0254 · 2021 · External reference
Is it time to screen all patients with hypertension for primary aldosteronism?
10.5694/mja17.00783 · 2018 · External reference
Renal dysfunction in primary aldosteronism: how, when, and who?
10.3390/kidneydial5010003 · 2025 · External reference
Current pattern of primary aldosteronism diagnosis
10.31128/ajgp-05-18-4587 · 2018 · External reference
Diagnostic delay and disease burden in primary aldosteronism: an international patient survey
10.1161/hypertensionaha.123.21965 · 2024 · External reference
The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline
10.1210/jc.2015-4061 · 2016 · External reference
Willingness to be tested for a secondary cause of hypertension: a survey of the Australian general community
10.1111/imj.15955 · 2023 · External reference
‘I can’t understand why others don’t screen more’: a qualitative study exploring why Australian general practitioners screen for primary aldosteronism
10.1136/bmjopen-2022-061671 · 2022 · External reference
The updated Consolidated Framework for Implementation Research based on user feedback
10.1186/s13012-022-01245-0 · 2022 · External reference
Assessing citation networks for dissemination and implementation research frameworks
10.1186/s13012-017-0628-2 · 2017 · External reference
A systematic review of the use of the Consolidated Framework for Implementation Research
10.1186/s13012-016-0437-z · 2016 · External reference
Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups
10.1093/intqhc/mzm042 · 2007 · External reference
Reflecting on reflexive thematic analysis
10.1080/2159676x.2019.1628806 · 2019 · External reference
Italian Society of Arterial Hypertension (SIIA). Screening of primary aldosteronism and pheochromocytoma among patients with hypertension: an Italian nationwide survey
10.1007/s40618-025-02532-5 · 2025 · External reference
Screening for primary aldosteronism in primary care: a scoping review
10.1093/fampra/cmae033 · 2024 · External reference
Cardiovascular and all-cause mortality outcomes of adrenalectomy versus medical treatment in primary aldosteronism: an umbrella review
10.1097/js9.0000000000002048 · 2024 · External reference
Adrenalectomy versus medical therapy in primary aldosteronism: a meta-analysis of long-term cardiac remodeling and function: medical versus adrenalectomy treatment compared in hyperaldosteronism (MATCH) study
10.1161/hypertensionaha.125.25104 · 2025 · External reference
Persistent cardiac organ damage in surgically and medically treated primary aldosteronism
10.1097/hjh.0000000000003135 · 2022 · External reference
Renal outcomes in medically and surgically treated primary aldosteronism
10.1161/hypertensionaha.118.11568 · 2018 · External reference
Impact of primary aldosteronism on kidney function: results from the SPAIN-ALDO registry
10.1097/hjh.0000000000003813 · 2024 · External reference
2020 International Society of Hypertension Global Hypertension Practice Guidelines
10.1161/hypertensionaha.120.15026 · 2020 · External reference
2018 ESC/ESH Guidelines for the management of arterial hypertension
10.1093/eurheartj/ehy339 · 2018 · External reference
2024 ESC Guidelines for the management of elevated blood pressure and hypertension
10.1093/eurheartj/ehae178 · 2024 · External reference
Primary aldosteronism: an Endocrine Society Clinical Practice Guideline
10.1210/clinem/dgaf284 · 2025 · External reference
Primary aldosteronism prevalence enhanced by strict adherence to 2016 Endocrine Society guidelines: insights from an endocrine hypertension unit
10.1097/hjh.0000000000003822 · 2024 · External reference
Cost-effectiveness of screening for primary aldosteronism in hypertensive patients in Australia: a Markov modelling analysis
10.1097/hjh.0000000000003513 · 2023 · External reference
Prevalence of hyperaldosteronism in primary care patients with resistant hypertension
10.3122/jabfm.2012.01.110099 · 2012 · External reference
